CHA2DS2-VASc score was not clearly linked with initiation of anticoagulation in humans (Patients with atrial fibrillation presenting to acute medical services) (OR 1.16, 95% CI 0.83–1.61; P = 0.38).
“The CHA2 DS2 -VASc score was not associated with being started on anticoagulation”
HumansPatients with atrial fibrillation presenting to acute medical servicesn = 613
CHA2DS2-VASc score is linked with a higher risk of noncardiovascular frail events in humans after adjusting for covariates in patients with AF (HR 2.1 (95% CI: 2.0-2.2)).
“CHA2DS2-VASc, and HAS-BLED > 0 were associated with higher risk of non-cardiovascular frail events (hazard ratio [HR] 2.1 (95% CI: 2.0-2.2) for CHA2DS2-VASc 4+”
Humansafter adjusting for covariates in patients with AF
CHA2DS2-VASc score is associated with lifespan in humans (coronary artery disease and atrial fibrillation) (1-year: 96.4% to 85.7%; 5-year: 78.4% to 50.0%).
“With the increase in the CHA2DS2-VASc score, the 1-year and 5-year survival rate decreased”
Humanscoronary artery disease and atrial fibrillationn = 1,579
Over an average 3.1 years, death, heart attack, stroke or heart-failure hospitalization occurred in 24.3% with sleep apnea versus 17.2% below the study’s threshold.Over an average 3.1 years, death, heart attack, stroke or heart-failure hospitalization occurred in 24.3% with sleep apnea versus 17.2% below the study’s threshold.
In 31,092 people with atrial fibrillation, an irregular heartbeat, followed for an average of 699 days, faster biological aging was linked to increased complications and…In 31,092 people with atrial fibrillation, an irregular heartbeat, followed for an average of 699 days, faster biological aging was linked to increased complications and death.